SEC Form 4 · accession 0001209191-17-040188
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul J Clancy
Director
Period of report
Jun 13, 2017
Accepted (ET)
Jun 15, 2017 · 5:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $50.73 | Jun 13, 2017 | A | 9,000 | A | — | Jun 12, 2027 | Common stock | 9,000 | 9,000 | D |
Explanation of responses
- F1This option was granted on June 13, 2017. The shares underlying this option vest as to 100% of the underlying shares on June 13, 2018.